INTEGRATION OF COMPLEMENTARY BIOMARKERS IN PATIENTS WITH FIRST EPISODE PSYCHOSIS: RESEARCH PROTOCOL OF A PROSPECTIVE FOLLOW UP STUDY

• Published in: Psychiatria Danubina Vol. 31; no. 2; pp. 162 - 171
• Main Authors: Rojnic Kuzman, Martina, Makaric, Porin, Bosnjak Kuharic, Dina, Kekin, Ivana, Rossini Gajsak, Linda, Boban, Marina, Bozina, Nada, Bozina, Tamara, Celic Ruzic, Mirela, Darmopil, Sanja, Filipcic, Igor, Ganoci, Lana, Hladnik, Ana, Madzarac, Zoran, Malojcic, Branko, Mihaljevic Peles, Alma, J. Mueller, Daniel, Ostojic, Drazenka, Petanjek, Zdravko, Petrovic, Ratimir, Vogrinc, Zeljka, Savic, Aleksandar, Silic, Ante, Sagud, Marina, Zivkovic, Maja, Bajic, Zarko
• Format: Journal Article Paper
• Language: English
• Published: Croatia Medicinska naklada 01.06.2019
• Subjects: biological markers; cortisole; first episode psychosis; neurocognition; schizophrenia; SPECT; stress; TCD
• ISSN: 0353-5053; 1849-0867
• DOI: 10.24869/psyd.2019.162

In this project, we recruited a sample of 150 patients with first episode of psychosis with schizophrenia features (FEP) and 100 healthy controls. We assessed the differences between these two groups, as well as the changes between the acute phase of illness and subsequent remission among patients over 18-month longitudinal follow-up. The assessments were divided into four work packages (WP): WP1- psychopathological status, neurocognitive functioning and emotional recognition; WP2- stress response measured by saliva cortisol during a stress paradigm; cerebral blood perfusion in the resting state (with single photon emission computed tomography (SPECT) and during activation paradigm (with Transcranial Ultrasonography Doppler (TCD); WP3-post mortem analysis in histologically prepared human cortical tissue of post mortem samples of subjects with schizophrenia in the region that synaptic alteration was suggested by WP1 and WP2; WP4- pharmacogenetic analysis (single gene polymorphisms and genome wide association study (GWAS). We expect that the analysis of these data will identify a set of markers that differentiate healthy controls from patients with FEP, and serve as an additional diagnostic tool in the first episode of psychosis, and prediction tool which can be then used to help tailoring individualized treatment options. In this paper, we describe the project protocol including aims and methods and provide a brief description of planned post mortem studies and pharmacogenetic analysis.